

Lung Cancer: Small Cell Lung Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op
 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

ECOG Performance Status: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (Select all that apply)

ALK Status: Negative Positive Not Reported

MET Amplification: Negative Positive Not Reported

EGFR: Negative Positive Not Reported

RET Gene Rearrangement: Absent Present Not Reported

BRAF: V600E Mutation V600K Mutation

ROS1 Rearrangement: Negative Positive Not Reported

Wild Type Not Reported

Limited Stage | Primary, Adjuvant, or First Line of Therapy (1st Line)

Carboplatin and etoposide ± XRT

Cisplatin and etoposide ± XRT

Extensive Stage | First Line of Therapy (1st Line)

Atezolizumab (Tecentriq), carboplatin, and etoposide

Carboplatin and etoposide

Second and Subsequent Lines of Therapy (2nd Line+) | Relapse Greater than Six (6) Months

Carboplatin and etoposide

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

